Literature DB >> 26471361

ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms.

Phillip L Palmbos1, Lidong Wang2, Huibin Yang2, Yin Wang2, Jacob Leflein2, McKenzie L Ahmet2, John E Wilkinson3, Chandan Kumar-Sinha4, Gina M Ney5, Scott A Tomlins4, Stephanie Daignault6, Lakshmi P Kunju4, Xue-Ru Wu7, Yair Lotan8, Monica Liebert9, Mats E Ljungman10, Diane M Simeone11.   

Abstract

Bladder cancer is a common and deadly malignancy but its treatment has advanced little due to poor understanding of the factors and pathways that promote disease. ATDC/TRIM29 is a highly expressed gene in several lethal tumor types, including bladder tumors, but its role as a pathogenic driver has not been established. Here we show that overexpression of ATDC in vivo is sufficient to drive both noninvasive and invasive bladder carcinoma development in transgenic mice. ATDC-driven bladder tumors were indistinguishable from human bladder cancers, which displayed similar gene expression signatures. Clinically, ATDC was highly expressed in bladder tumors in a manner associated with invasive growth behaviors. Mechanistically, ATDC exerted its oncogenic effects by suppressing miR-29 and subsequent upregulation of DNMT3A, leading to DNA methylation and silencing of the tumor suppressor PTEN. Taken together, our findings established a role for ATDC as a robust pathogenic driver of bladder cancer development, identified downstream effector pathways, and implicated ATDC as a candidate biomarker and therapeutic target. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26471361      PMCID: PMC4668224          DOI: 10.1158/0008-5472.CAN-15-0603

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.

Authors:  Lars Dyrskjøt; Mogens Kruhøffer; Thomas Thykjaer; Niels Marcussen; Jens L Jensen; Klaus Møller; Torben F Ørntoft
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

Review 2.  Focus on bladder cancer.

Authors:  Colin P N Dinney; David J McConkey; Randall E Millikan; Xifeng Wu; Menashe Bar-Eli; Liana Adam; Ashish M Kamat; Arlene O Siefker-Radtke; Tomasz Tuziak; Anita L Sabichi; H Barton Grossman; William F Benedict; Bogdan Czerniak
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

Review 3.  Urothelial tumorigenesis: a tale of divergent pathways.

Authors:  Xue-Ru Wu
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

4.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Authors:  Lan Mo; Xiaoyong Zheng; Hong-Ying Huang; Ellen Shapiro; Herbert Lepor; Carlos Cordon-Cardo; Tung-Tien Sun; Xue-Ru Wu
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

5.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.

Authors:  Marta Sanchez-Carbayo; Nicholas D Socci; Juanjo Lozano; Fabien Saint; Carlos Cordon-Cardo
Journal:  J Clin Oncol       Date:  2006-01-23       Impact factor: 44.544

6.  Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation.

Authors:  Z T Zhang; J Pak; H Y Huang; E Shapiro; T T Sun; A Pellicer; X R Wu
Journal:  Oncogene       Date:  2001-04-12       Impact factor: 9.867

7.  Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.

Authors:  Hiroshi Tsuruta; Hiroyuki Kishimoto; Takehiko Sasaki; Yasuo Horie; Miyuki Natsui; Yoshiko Shibata; Koichi Hamada; Nobuyuki Yajima; Koichi Kawahara; Masato Sasaki; Norihiko Tsuchiya; Katsuhiko Enomoto; Tak Wah Mak; Toru Nakano; Tomonori Habuchi; Akira Suzuki
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

8.  Molecular classification of human carcinomas by use of gene expression signatures.

Authors:  A I Su; J B Welsh; L M Sapinoso; S G Kern; P Dimitrov; H Lapp; P G Schultz; S M Powell; C A Moskaluk; H F Frierson; G M Hampton
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

9.  Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.

Authors:  Craig D Logsdon; Diane M Simeone; Charles Binkley; Thiruvengadam Arumugam; Joel K Greenson; Thomas J Giordano; David E Misek; Rork Kuick; Samir Hanash
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

10.  Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Scott A Tomlins; Vasudeva Mahavisno; Nicole Kasper; Radhika Varambally; Terrence R Barrette; Debashis Ghosh; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

View more
  26 in total

1.  Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers.

Authors:  Alex Panaccione; Yan Guo; Wendell G Yarbrough; Sergey V Ivanov
Journal:  Clin Breast Cancer       Date:  2017-01-27       Impact factor: 3.225

2.  TRIM58 suppresses the tumor growth in gastric cancer by inactivation of β-catenin signaling via ubiquitination.

Authors:  Xiaowen Liu; Ziwen Long; Hong Cai; Shengjia Yu; Jianghong Wu
Journal:  Cancer Biol Ther       Date:  2019-11-21       Impact factor: 4.742

3.  microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.

Authors:  Guang-Cheng Guo; Jia-Xiang Wang; Ming-Li Han; Lian-Ping Zhang; Lin Li
Journal:  Cell Oncol (Dordr)       Date:  2017-01-04       Impact factor: 6.730

4.  3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer.

Authors:  Yin Wang; Mark L Day; Diane M Simeone; Phillip L Palmbos
Journal:  J Vis Exp       Date:  2018-09-13       Impact factor: 1.355

5.  Identification of a role for TRIM29 in the control of innate immunity in the respiratory tract.

Authors:  Junji Xing; Leiyun Weng; Bin Yuan; Zhuo Wang; Li Jia; Rui Jin; Hongbo Lu; Xian Chang Li; Yong-Jun Liu; Zhiqiang Zhang
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

6.  TRIM29 Negatively Regulates the Type I IFN Production in Response to RNA Virus.

Authors:  Junji Xing; Ao Zhang; Laurie J Minze; Xian Chang Li; Zhiqiang Zhang
Journal:  J Immunol       Date:  2018-05-16       Impact factor: 5.422

7.  TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer.

Authors:  Rui Xu; Jingye Hu; Tiansong Zhang; Chao Jiang; Hui-Yun Wang
Journal:  Oncotarget       Date:  2016-05-10

Review 8.  Unmasking molecular profiles of bladder cancer.

Authors:  Xuan-Mei Piao; Young Joon Byun; Wun-Jae Kim; Jayoung Kim
Journal:  Investig Clin Urol       Date:  2018-02-01

9.  miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.

Authors:  Wan Li; Jie Yi; Xiangjin Zheng; Shiwei Liu; Weiqi Fu; Liwen Ren; Li Li; Dave S B Hoon; Jinhua Wang; Guanhua Du
Journal:  Clin Epigenetics       Date:  2018-05-16       Impact factor: 7.259

10.  miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3.

Authors:  Jun Chen; Chao Zhou; Junhe Li; Xiaojun Xiang; Ling Zhang; Jun Deng; Jianping Xiong
Journal:  Int J Mol Med       Date:  2018-01-18       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.